Colorectal Cancer is cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus). In the United States, it is the fourth most common cancer in men and women. Caught early, it is often curable.
According to a study, DNA defects in the energy “factories” of a cell increase the chance of survival in patients suffering from bowel cancer.
Researchers have explained mechanisms that play a role in maintaining the embryonic stem cells in the most optimized state for use in regenerative medicine.
Oncotarget published "Ibuprofen disrupts a WNK1/GSK3β/SRPK1 protein complex required for expression of tumor-related splicing variant RAC1B in colorectal cells" which reported that although the molecular mechanism behind the antitumor properties of NSAIDs has been largely attributed to inhibition of cyclooxygenases , several studies have shown that the chemopreventive properties of ibuprofen also involve multiple COX-independent effects.
A study headed by UCM reports that polymorphisms in gene TGFB1 and low plasma levels of protein TGFB1 serve as biomarkers for the gastric adenocarcinoma prognosis.
A machine learning algorithm helps accurately differentiate benign and premalignant colorectal polyps on CT colonography scans, according to a study published in the journal Radiology.
Developing “super soldiers” of particular white blood cells to promote an anti-tumor reaction has been demonstrated in a series of well-designed experiments.
Most tumors consist of a heterogenous mix of cells. Genetic mutations found only in some of these cells are known to aid with the spread and progression of cancer.
Neanderthals' gut microbiota already included some beneficial micro-organisms that are also found in our own intestine.
New research and analysis appearing in the Journal of the Academy of Nutrition and Dietetics, published by Elsevier, highlights the barriers cancer survivors face in maintaining a healthy diet, as well as the role nutrition may play in cancer risk and treatment.
Researchers at the Francis Crick Institute, the UCL Cancer Institute, and the Cancer Research UK Lung Cancer Centre of Excellence have identified genetic changes in tumours which could be used to predict if immunotherapy drugs would be effective in individual patients.
Researchers at the University of Helsinki have defined a cancer invasion machinery, which is orchestrated by a frequently mutated cancer gene called Ras. When signaling from Ras protein becomes abnormally high, like it does in many cancers, this switches on the cellular machinery that helps the cancer cells to depart from the tissue from which the cells have developed.
The abundant presence of an enzyme known as low molecular weight protein tyrosine phosphatase (LMWPTP) in tumor cells has long been considered an indicator of cancer aggressiveness and metastatic potential.
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination - of irinotecan, cetuximab, and vemurafenib - is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.
New research has shown how microbubbles carrying powerful cancer drugs can be guided to the site of a tumour using antibodies.
The first study to compare molecular landscapes of early-onset and late-onset appendiceal cancer has revealed distinct non-silent mutations in the tumors of younger patients, setting the stage for the development of potential therapeutic advances for this rare disease.
As time goes by, the tips of your chromosomes--called telomeres--become shorter. This process has long been viewed as an unwanted side-effect of aging, but a recent study shows it is in fact good for you.
Cancer immunotherapies, which empower patients' immune systems to eliminate tumors, are revolutionizing cancer treatment. Many patients respond well to these treatments, sometimes experiencing long-lasting remissions. But some cancers remain difficult to treat with immunotherapy, and expanding the impact of the approach is a high priority.
In breakthrough colon cancer research, scientists at ChristianaCare's Helen F. Graham Cancer Center & Research Institute have discovered a link between two key signaling pathways crucial to the development and growth of colon cancer. The study is published today in the journal PLOS ONE.
Scientists have shown that cancer rebuilds the architecture of human chromosomes, which allows the disease to take hold and spread.
Scientists have detected a molecular connection between dairy and meat diets and the development of antibodies in the blood that raises the risk of cancer.